References
- A´lvarez R, Puebla P, Diaz JF, et al. (2013). Endowing indole-based tubulin inhibitors with an anchor for derivatization: highly potent 3-substituted indolephenstatins and indoleisocombretastatins. J Med Chem 56:2813–27
- Carlson RO, (2008).New tubulin targeting agents currently in clinical development. Expert Opinon investig Drugs 15:707–22
- DeSantis CE, Lin CC, Mariotto AB, et al. (2014). Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252–71
- Downing KH. (2000). Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Div Biol 16:89–111
- Duan YT, Man RJ, Tang DJ, et al. (2016). Design, synthesis and antitumor activity of novel link-bridge and b-ring modified combretastatin a-4 (ca-4) analogues as potent antitubulin agents. Sci Rep 6:25387
- Jordan MA, Wilson L. (2004). Microtubules as a target for anticancer drugs. Nature Rev Cancer 4:253
- Kaur R, Kaur G, Gill RK, et al. (2014). Recent developments in tubulin polymerization inhibitors: an overview. Eur J Med Chem 87:89–124
- Lin J, Yao L, Lame M, et al. (2006). The increased emphasis of ADME properties in hit-to-lead drug discovery. Acta Pharmacol Sin 27:450
- Mahboobi S, Sellmer A, Beckers T. (2006). Development of tubulin inhibitors as antimitotic agents for cancer therapy. Stud Nat Prod Chemy 33:719–50
- Miller KD, Siegel RL, Lin CC, et al. (2016). Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–89
- Pellegrini F, Budman DR. (2005). Tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23:264–73
- Perez EA, Mooberry S, Twelves C, et al. (2011). New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois. Clin Adv Hematol Oncol 2011;9(8 Suppl 20):1
- Qin YJ, Li YJ, Jiang AQ, et al. (2015). Design, synthesis and biological evaluation of novel pyrazoline-containing derivatives as potential tubulin assembling inhibitors. Eur J Med Chem 94:447–57
- Schaletzky J, Rape M. (2016). Getting a grip on microtubules. Cell 164:836–7
- Selick HE, Beresford AP, Tarbit MH. (2002). The emerging importance of predictive ADME simulation in drug discovery. Drug Discov Today 7.2:109–16
- Siegel RL, Miller KD, Jemal A. (2015). Cancer statistics, 2015. CA Cancer J Clin 65:5–29
- Simoni D, Romagnoli R, Baruchello R, et al. (2008). Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity. J Med Chem 51:6211–15
- Sui X, Chen R, Wang Z, et al. (2013). Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 4:e838
- Tahir SK, Nukkala MA, Mozny NAZ, et al. (2003). Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative. Mol Can Ther 2:227–33
- Vineis P, Wild CP. (2014). Global cancer patterns: causes and prevention. The Lancet 383:549–57
- Wang X, Chen Z, Che J, et al. (2009). Development of a rapid and sensitive LC–MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study. J Chromatogr B 877:3813–21
- Wang YT, Qin YJ, Yang N, et al. (2015). Synthesis, biological evaluation, and molecular docking studies of novel 1-benzene acyl-2-(1-methylindol-3-yl)-benzimidazole derivatives as potential tubulin polymerization inhibitors. Eur J Med Chem 99:125–37
- Zhang YL, Qin YJ, Tang DJ, et al. (2016). Synthesis and biological evaluation of 1-Methyl-1H-indole-Pyrazoline Hybrids as Potential Tubulin Polymerization Inhibitors . Chem Med Chem 11:1446–58
- Zweifel M, Jayson GC, Reed NS, et al. (2011). Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22:2036–41